LumiraDx
Top Five Articles on 360Dx Last Week: Roche Acquires LumiraDx POC Tech, Rapid Sepsis Tests, More
Last week, readers were most interested in a story about Roche's proposed purchase of troubled company LumiraDx's POC technology.
LumiraDx Shares to be Delisted From Nasdaq
The decision by Nasdaq follows the sale of essentially all of LumiraDx's assets to Roche.
360Dx Top 30 Falls 5 Percent in 2023
Of the 30 companies in the index, nine saw their share prices rise, while 20 saw their share prices decline and one was flat year over year.
Roche to Acquire LumiraDx Point-of-Care Testing Tech for up to $350M
Roche expects to integrate the POC clinical chemistry and immunoassay tests into its Diagnostics business when the acquisition closes in mid-2024.
360Dx Top 30 Continues Upward Climb, Increases 6 Percent in December
Of the 30 companies in the index, 22 saw their share prices increase, four saw their stock prices decline, and four were flat month over month.
Jul 5, 2023
360Dx Top 30 Rebounds in June, Rising 4 Percent
Jun 1, 2023
360Dx Top 30 Drops 6 Percent in May
May 1, 2023
360Dx Top 30 Slides 2 Percent in April
Apr 3, 2023
360Dx Top 30 Rebounds 2 Percent in March
Mar 21, 2023